AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
With a market cap of 251.39B, AstraZeneca(AZN) trades at $162.91. The stock has a price-to-earnings ratio of 24.06 and currently yields dividends of 1.93%.
On 2026-09-01, AstraZeneca(AZN) stock moved within a range of $160.99 to $162.98. With shares now at $162.91, the stock is trading +1.2% above its intraday low and -0.0% below the session's peak.
Trading activity shows a volume of 75.54K, compared to an average daily volume of 3.25M.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
AZN News
...
AstraZeneca (AZN) announced the completion of the exclusive license agreement with Dizal Pharmaceutical for Zegfrovy – sunvozertinib -, an oral irreversible epi...
AstraZeneca ( (GB:AZN) ) has issued an announcement. AstraZeneca and Daiichi Sankyo have secured European Commission approval for Enhertu (trastuzumab deruxtec...
Analyst ratings
100%
of 10 ratingsMore AZN News
AstraZeneca ( (GB:AZN) ) has issued an announcement. AstraZeneca has appointed Wan Ling Martello as a Non-Executive Director, effective 1 September 2026, and s...
AstraZeneca ( (GB:AZN) ) has issued an update. AstraZeneca has completed its exclusive global licensing deal with Dizal Pharmaceutical for Zegfrovy (sunvozerti...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The Prospective Observational Multicenter Study of Patients With Arterial Hypertension...
LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00. Gaurav Maini has given his Buy rati...
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? 8/27/2026 Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease t...
Key Points Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The company is busy bringing out new drugs and develop...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is running a Phase II trial called “A Phase II, Randomized,...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.